Spots Global Cancer Trial Database for Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin

Official Title: Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm

Study ID: NCT00601640

Conditions

Other Benign Neoplasm of Skin, Unspecified

Interventions

Diclofenac Na gel

Eflornithine HCL ointment

Study Description

Brief Summary: RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of eflornithine and diclofenac may stop cancer from growing in patients with sun-damaged skin. PURPOSE: This randomized phase II trial is studying the side effects and how well eflornithine works compared with diclofenac, given alone or together, in treating patients with sun-damaged skin.

Detailed Description: OBJECTIVES: Primary * To determine if combination therapy with topical eflornithine hydrochloride ointment and topical diclofenac sodium gel over 3-months increases the efficacy versus either agent used alone in the treatment of moderately sun-damaged skin. Secondary * To evaluate the safety of sequential administration of topical eflornithine hydrochloride ointment and topical diclofenac sodium gel. * To determine the correlation of karyometric changes with histopathologic, immunohistochemical, clinical, and genetic polymorphism data. * To obtain materials for microarray analysis. OUTLINE: Patients are randomized to 1 of 3 treatment arms. * Eflornithine hydrochloride : Patients apply topical eflornithine hydrochloride ointment to their left forearm twice daily on days 1-90. * Diclofenac sodium : Patients apply topical diclofenac sodium gel to their left forearm once daily on days 1-90. * Eflornithine hydrochloride/Diclofenac sodium : Patients apply topical eflornithine hydrochloride ointment as in arm I twice daily and topical diclofenac sodium gel as in arm II once daily on days 1-90. Prior to treatment, three 4-mm punch biopsies are taken from the skin of the left lateral forearm for assessment of histopathology, the cyclooxygenase-2 enzyme and p53 expression, apoptosis, and nuclear chromatin karyometry. Tissue is also obtained for future use in microarray analysis. Blood is drawn for assessment of ornithine decarboxylase polymorphisms and for banking for subsequent studies. Biopsies are repeated 2-3 weeks after completion of treatment. Digital photographs are taken at baseline and 1-2 weeks after completion of study therapy to document improvement of sun damage, appearance of new skin lesions, and toxicity.